Core Viewpoint - The market demand for polylactic acid (PLA) fiber is steadily increasing due to rising consumer awareness of environmental protection and a global pursuit of sustainable development. The market size in China is projected to reach approximately 4.511 billion yuan in 2024, with a year-on-year growth of 3.9%, and is expected to grow to 6.979 billion yuan by 2030 [1][20]. Industry Overview - PLA fiber is produced from starch-containing agricultural products such as corn and wheat, which are fermented to generate lactic acid, then polymerized and spun into fibers. It is a biodegradable synthetic fiber that can decompose into carbon dioxide and water in the environment [4][16]. - The fiber has excellent properties such as good hand feel, UV resistance, low flammability, and excellent processing performance, making it suitable for various applications including fashion, sportswear, and hygiene products [6][7]. Market Size and Growth - The PLA fiber industry in China is expected to maintain strong growth momentum, with the market size projected to reach approximately 6.979 billion yuan by 2030 [1][20]. - The market demand for PLA fiber will continue to expand due to increasing consumer environmental awareness and ongoing government support for the environmental industry [20]. Production Process - The production of PLA fiber involves extracting starch from biomass materials, fermenting it to produce lactic acid, and then polymerizing it into PLA, which is subsequently spun into fibers [8][10]. Industry Development History - The research and development of PLA fiber have a history of over half a century, with significant advancements made by various companies in the field, including those in China [12][22]. Industry Chain - The PLA fiber industry chain includes upstream raw materials (corn, wheat, etc.), midstream production processes, and downstream applications in textiles, medical devices, and packaging [14][16]. Key Companies - Major companies in the PLA fiber industry include Anhui Fengyuan Group, Ma'anshan Tongjie Liang Biological Materials Co., Ltd., and Zhejiang Haizheng Biological Materials Co., Ltd., among others [2][22][24]. Industry Trends - The PLA fiber industry is moving towards high performance, with a focus on enhancing heat resistance, mechanical strength, and functional properties through molecular structure modification and composite processing technologies [29]. - The application of PLA fiber is diversifying beyond textiles to include biodegradable wipes, medical dressings, and packaging materials, driven by the deepening "plastic ban" policies [30][31].

证券日报网讯溢多利（300381）7月29日在互动平台回答投资者提问时表示，截至2025年7月18日，公司 股东总数为21304户。 ...

广东溢多利生物科技股份有限公司 证券投资管理制度 第一章 总则 第一条 为规范广东溢多利生物科技股份有限公司（以下简称"公司"）的 证券投资行为，建立完善有序的投资决策管理机制，有效防范投资风险，强化 风险控制，保证公司资金、财产安全，维护投资者和公司合法权益，根据《中 华人民共和国公司法》《中华人民共和国证券法》《深圳证券交易所创业板股票 上市规则》等法律法规和《广东溢多利生物科技股份有限公司章程》（以下简 称"《公司章程》"）的有关规定，结合公司的实际情况，制定本制度。 第二条 本制度所称证券投资，是指公司在法律法规规定允许的情况下， 在控制投资风险的前提下，以提高资金使用效率和收益最大化为原则，在境内 外证券市场投资证券、衍生品的行为，包括新股配售或者申购、证券回购、股 票及存托凭证投资、债券投资以及深圳证券交易所认定的其他投资行为。 以下情形不适用本制度： （一）固定收益类或者承诺保本的投资行为； （二）参与其他上市公司的配股或者行使优先认购权利； （三）购买其他上市公司股份超过总股本的 10%，且拟持有三年以上的证 券投资； （四）公司首次公开发行股票并上市前已进行的投资。 第三条 本制度适用于公司 ...

股票代码：300381 股票简称：溢多利 公告编号：2025-036 广东溢多利生物科技股份有限公司 重要内容提示： 1．投资种类：广东溢多利生物科技股份有限公司（以下简称"公司"）及 控股子公司拟使用自有资金开展证券投资的种类包括新股配售或者申购、证券 回购、股票及存托凭证投资、债券投资以及深圳证券交易所认定的其他投资产 品。 2．投资金额：公司及控股子公司拟使用不超过人民币 3,000 万元（含本 数）自有资金开展证券投资，在上述额度内，资金可以滚动使用，但期限内任 一时点的交易金额（含前述投资的收益进行再投资的相关金额）不得超过上述 额度。 3．特别风险提示：公司及控股子公司进行证券投资可能面临的风险包括 但不限于市场风险、流动性风险、操作风险等，公司将积极落实内部控制制度 和风险防范措施，审慎进行证券投资，敬请投资者充分关注投资风险。 一、投资情况概述 1．投资目的：为提高自有资金使用效率、增加股东回报，在充分保障公 司及控股子公司日常经营的资金需求并有效控制风险的前提下，公司及控股子 公司将使用闲置自有资金开展证券投资，增加资金收益。 关于使用闲置自有资金开展证券投资的公告 本公司及董事会全体成员保 ...

一、董事会会议召开情况 广东溢多利生物科技股份有限公司（以下简称"公司"）第八届董事会第 十二次会议于 2025 年 7 月 28 日在公司会议中心以现场和通讯相结合的方式 召开。会议通知于 2025 年 7 月 17 日以信息、邮件等方式发送至公司全体董 事。会议应出席董事 7 名，实际出席会议董事 7 名，公司监事、部分高级管理 人员列席了本次会议。会议由董事长陈少美先生主持。本次会议符合《公司法》 和《公司章程》的有关规定，会议合法有效。 二、董事会会议审议情况 本次会议以投票表决方式审议通过了如下议案： 股票代码：300381 股票简称：溢多利 公告编号：2025-035 广东溢多利生物科技股份有限公司 第八届董事会第十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 范投资风险，强化风险控制，保证公司资金、财产安全，维护投资者和公司合 法权益，董事会根据《中华人民共和国证券法》《深圳证券交易所创业板股票 上市规则》等法律法规《公司章程》的有关规定，结合公司的实际情况，制定 了《证券投资管理制度》，具体内容详见公司在巨潮资讯网(www. ...

Core Insights - The baking enzyme preparation industry in China is experiencing rapid growth driven by the expanding market for baked goods and increasing consumer demand for healthy, functional products, particularly low-sugar and high-fiber options [1][14] - The market size of China's baking enzyme preparation industry is projected to reach approximately 2.15 billion yuan in 2024, with a year-on-year growth of 15%, and is expected to further grow to 2.48 billion yuan by 2025 [14] - The industry is characterized by a complete supply chain, including upstream raw material supply, midstream production, and downstream applications, with significant advancements in technology and product innovation [6][12] Industry Overview - Baking enzyme preparations are natural protein catalysts extracted through biotechnology, aimed at improving the quality, processing performance, and nutritional value of baked goods [2][3] - These enzymes enhance dough extensibility, fermentation efficiency, delay aging, and optimize texture by breaking down components such as starch, protein, or cellulose [2][3] - The main types of baking enzymes include amylases, proteases, xylanases, lipases, and glucose oxidases, sourced from microorganisms or plants, known for their efficiency and safety [2][3] Market Dynamics - The retail market for baked goods in China is expected to reach 611.07 billion yuan in 2024, growing at a rate of 8.8%, with health-oriented and scenario-based products becoming new consumer hotspots [8] - The number of baking stores in China is projected to increase from 285,000 in 2020 to 338,000 by 2025, although the annual growth rate has slowed from 5.6% to 0.6% [10] - The enzyme preparation industry is expected to produce 2.074 million tons in 2024, reflecting a year-on-year growth of 7.5%, with food industry applications maintaining a 42.3% market share [12][14] Competitive Landscape - The baking enzyme preparation industry in China is characterized by a competitive landscape where international giants dominate the high-end market, while domestic companies are rapidly catching up [18][20] - Major international brands like Novozymes and Genencor lead the high-end market, while domestic firms such as Yidoli and Blue Biological are making strides in basic enzyme products and gradually moving into high-end fields [18][20] - The market concentration is increasing, with the East China region accounting for over 60% of the market share, driven by technological advancements and economies of scale [18][20] Development Trends - The industry is evolving towards high-end technology, health sustainability, and global market integration, with innovations in biotechnology driving the development of efficient and stable enzyme preparations [23][24] - There is a growing demand for functional enzyme preparations that cater to health-conscious consumers, with a shift towards low-sensitivity and high-fiber products [24] - The domestic market is expanding, particularly in the eastern regions, while companies are also establishing production facilities in Southeast Asia to leverage local resources and reduce costs [25]

3、在保证本次权益分派方案不变的前提下，2024 年度权益分派实施后的 除权除息价格按照上述原则及计算方式执行，即本次权益分派实施后的除权除 息价格=股权登记日收盘价-0.0977828 元/股。 一、股东大会审议通过本次权益分派方案的情况 1、公司于 2025 年 5 月 12 日召开 2024 年度股东大会，审议通过了《关于 公司 2024 年度利润分配预案的议案》，具体方案如下： 股票代码：300381 股票简称：溢多利 公告编号：2025-034 广东溢多利生物科技股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、广东溢多利生物科技股份有限公司（以下简称"公司"）2024 年度权益 分派方案已获 2025 年 5 月 12 日召开的 2024 年度股东大会审议通过。 2、公司回购专户中的股份不参与本次权益分派。公司以现有总股本扣减 已回购股份 10,887,600 股后的股本 480,173,861 股为基数，向全体股东每 10 股 派 1.00 元人民币现金（含税），共计派发现金红利 48 ...

Core Viewpoint - The legal opinion provided by Beijing Deheng (Shenzhen) Law Firm confirms that the 2024 annual general meeting of Guangdong Yidoli Biotechnology Co., Ltd. was convened and conducted in compliance with relevant laws and regulations, ensuring the legitimacy of the meeting and its resolutions [1][16]. Group 1: Meeting Procedures - The annual general meeting is scheduled for May 12, 2025, and the notice was published in accordance with legal requirements, with a 20-day notice period before the meeting [5]. - The meeting was held at the company's conference center in Zhuhai, and the actual time and location matched the notice provided [5][6]. - The network voting was conducted on the same day, with specific time slots for voting through different systems [6]. Group 2: Attendance and Qualifications - A total of 109 participants attended the meeting, representing 168,542,143 shares, which is 35.1002% of the total voting shares [7]. - Among the attendees, 4 participants were present at the physical meeting, representing 143,687,478 shares (29.9241%), while 105 participated via online voting, representing 24,854,665 shares (5.1762%) [7]. - The qualifications of the attendees and the convenor of the meeting were verified and deemed valid according to relevant laws and regulations [8]. Group 3: Voting Procedures and Results - The voting process included both on-site and online voting, with no modifications to the agenda items as listed in the notice [9]. - The voting was conducted in accordance with legal requirements, with representatives overseeing the counting of votes [9]. - The resolutions passed included the approval of the 2024 annual report, with 99.5046% of votes in favor, and other key reports also received similar overwhelming support [10][11][12][13][14][15][16].

关于广东溢多利生物科技股份有限公司 2024 年年度股东大会的 法律意见 北京德恒（深圳）律师事务所 深圳市福田区金田路 4018 号安联大厦 B 座 11 层 电话:0755-88286488 传真:0755-88286499 邮编:518026 ————————————————————————————— ————————————————————————————— 北京德恒（深圳）律师事务所 关于广东溢多利生物科技股份有限公司 2024 年年度股东大会的法律意见 北京德恒（深圳）律师事务所 关于广东溢多利生物科技股份有限公司 2024 年年度股东大会的 法律意见 德恒 06G20240488-0002 号 致：广东溢多利生物科技股份有限公司 广东溢多利生物科技股份有限公司（以下简称"公司"）2024 年年度股东大会（以 下简称"本次股东大会"）于 2025 年 5 月 12 日（星期一）召开。北京德恒（深圳） 律师事务所（以下简称"德恒"或"本所"）受公司委托，指派浦洪律师、何雪华律 师（以下简称"本所律师"）列席了本次股东大会。根据《中华人民共和国证券法》 （以下简称"《证券法》"）《中华人民共和国公司法 ...

股票代码：300381 股票简称：溢多利 公告编号：2025-033 广东溢多利生物科技股份有限公司 2024 年年度股东大会决议公告 特别提示 1、本次股东大会召开期间没有增加、否决或变更提案； 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 公司股东只能选择上述投票方式中的一种表决方式。同一表决权出现重复 投票的，以第一次有效表决结果为准。 4、会议召集人：公司董事会 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开情况 1、会议召开时间： 现场会议时间：2025 年 5 月 12 日（星期一）下午 2:30 网络会议时间：2025 年 5 月 12 日。其中，通过深圳证券交易所交易系统 进行网络投票的时间为 2025 年 5 月 12 日 9:15-9:25，9:30-11:30，13:00-15:00； 通过深圳证券交易所互联网系统投票的具体时间为 2025 年 5 月 12 日 9:15 至 15:00 的任意时间。 2、现场会议召开地点：珠海市南屏科技园屏北一路 8 号公司会议中心。 3、会议召开和投票方式：现场投票与网络投票相结 ...